Home/Filings/4/0001415889-25-001046
4//SEC Filing

Lizzul Paul F. 4

Accession 0001415889-25-001046

CIK 0001370053other

Filed

Jan 6, 7:00 PM ET

Accepted

Jan 7, 5:33 PM ET

Size

19.7 KB

Accession

0001415889-25-001046

Insider Transaction Report

Form 4
Period: 2025-01-03
Lizzul Paul F.
Chief Medical Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2025-01-06+6,14527,904 total
  • Exercise/Conversion

    Restricted Stock Unit

    2025-01-0310,55531,665 total
    Common Stock (10,555 underlying)
  • Exercise/Conversion

    Restricted Stock Unit

    2025-01-066,14512,290 total
    Common Stock (6,145 underlying)
  • Award

    Restricted Stock Unit

    2025-01-07+34,10034,100 total
    Common Stock (34,100 underlying)
  • Exercise/Conversion

    Common Stock

    2025-01-03+10,55526,095 total
  • Tax Payment

    Common Stock

    2025-01-03$14.60/sh4,336$63,30621,759 total
  • Tax Payment

    Common Stock

    2025-01-06$15.30/sh2,261$34,59325,643 total
  • Award

    Stock Option (right to buy)

    2025-01-07+97,20097,200 total
    Exercise: $14.83Exp: 2035-01-06Common Stock (97,200 underlying)
Footnotes (8)
  • [F1]Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
  • [F2]Reflects the acquisition of 142 shares acquired under the Company's ESPP.
  • [F3]Represents shares withheld by the Issuer to satisfy a portion of the tax withholding obligation in connection with the vesting of RSUs and do not represent discretionary transactions by the Reporting Person. Following the transactions reflecting in this Form 4, no additional transactions are expected to satisfy the Reporting Person's tax withholding obligation.
  • [F4]The Reporting Person did not sell or otherwise dispose of any of the shares with respect to the vesting of RSUs reported on this Form 4 for any reason other than to cover required taxes.
  • [F5]The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
  • [F6]The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
  • [F7]The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
  • [F8]The stock option vests as to 25% of the total shares on January 7, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Issuer

ANAPTYSBIO, INC

CIK 0001370053

Entity typeother

Related Parties

1
  • filerCIK 0001711462

Filing Metadata

Form type
4
Filed
Jan 6, 7:00 PM ET
Accepted
Jan 7, 5:33 PM ET
Size
19.7 KB